Mystery Solved? GenSight’s Gene Therapy Does Move Between Eyes
Company hopes to file in Europe next year
Executive Summary
Company boosted by animal study which helps answer riddle of improvement in untreated eye.
You may also be interested in...
REFLECT Study Confirms Efficacy Of GenSight's Gene Therapy Lumevoq
French biotech GenSight Biologics reports top-line results from the Phase III REFLECT study, backing the efficacy of its lead gene therapy in a devastating eye disease, and prepares plans to commercialize the product.
GenSight Undeterred By Gene Therapy’s Placebo Puzzle
Phase III success at 96 weeks sets up GenSight blindness therapy for EU filing, but puzzle of placebo arm benefits remain
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.